Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis.
Cardiac AA amyloidosis
Heart failure
Left ventricular hypertrophy
Rheumatoid arthritis
Tocilizumab
Journal
Journal of cardiology cases
ISSN: 1878-5409
Titre abrégé: J Cardiol Cases
Pays: Japan
ID NLM: 101549579
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
28
06
2021
revised:
14
08
2021
accepted:
02
09
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
epublish
Résumé
Because cardiac involvement of amyloid A (AA) is not frequent, little is known about the effects of tocilizumab (TCZ; a humanized monoclonal anti-interleukin-6 receptor antibody). We present the case of a 77-year-old man with cardiac AA amyloidosis due to rheumatoid arthritis (RA). He was admitted to our hospital because of gastrointestinal bleeding. Upon admission, chest radiography and electrocardiogram showed progression of cardiomegaly and atrioventricular conduction delay, respectively. Echocardiography showed diffuse left ventricular (LV) hypertrophy with reduced LV contraction. AA amyloid deposits in the myocardium were identified by Congo red staining and immunohistochemical staining with anti-AA antibody, suggesting cardiac AA amyloidosis. After starting treatment with TCZ, his condition improved. Hypertrophic LV mass was significantly reduced, and impaired LV contraction was restored after 10 months of TCZ treatment. The effects of TCZ were sustained for 2 years. Plasma N terminal pro-B-type natriuretic peptide level decreased from 2947 pg/mL (reference level, <125 pg/mL) on admission to 325 pg/mL after 2 years of TCZ treatment. The present case supports that cardiac biopsy is very important to diagnose cardiac AA amyloidosis in patients with RA complicating unexplained cardiac hypertrophy and/or dysfunction and TCZ should be administered if applicable. <
Identifiants
pubmed: 35261706
doi: 10.1016/j.jccase.2021.09.001
pii: S1878-5409(21)00146-8
pmc: PMC8888710
doi:
Types de publication
Case Reports
Langues
eng
Pagination
177-181Informations de copyright
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest in the publication of this manuscript.
Références
Mod Rheumatol. 2014 Jan;24(1):137-43
pubmed: 24261770
Amyloid. 2015;22(2):84-92
pubmed: 25585627
Mod Rheumatol. 2019 Mar;29(2):268-274
pubmed: 30132351
J Rheumatol. 2003 May;30(5):948-51
pubmed: 12734887
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3186-3187
pubmed: 32435877
N Engl J Med. 2007 Jun 7;356(23):2349-60
pubmed: 17554116
Biol Pharm Bull. 2007 Nov;30(11):2001-6
pubmed: 17978466
Arthritis Rheum. 2001 Jan;44(1):66-72
pubmed: 11212178
N Engl J Med. 2007 Jun 7;356(23):2361-71
pubmed: 17554117
Intern Med. 2018 Dec 1;57(23):3351-3355
pubmed: 30101921